CenterBook Partners LP Has $9.13 Million Holdings in Establishment Labs Holdings Inc. $ESTA

CenterBook Partners LP lessened its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 41.3% in the third quarter, Holdings Channel.com reports. The firm owned 222,845 shares of the company’s stock after selling 156,540 shares during the period. CenterBook Partners LP’s holdings in Establishment Labs were worth $9,134,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State of Wyoming acquired a new position in shares of Establishment Labs during the third quarter worth about $71,000. Osaic Holdings Inc. raised its position in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the last quarter. CWM LLC lifted its stake in Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after acquiring an additional 686 shares in the last quarter. Brian Low Financial Group LLC bought a new stake in Establishment Labs in the 3rd quarter valued at approximately $223,000. Finally, Patriot Financial Group Insurance Agency LLC boosted its position in Establishment Labs by 5.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock worth $261,000 after acquiring an additional 350 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Stock Down 0.3%

Shares of ESTA stock opened at $74.34 on Wednesday. The company has a debt-to-equity ratio of 15.06, a quick ratio of 2.10 and a current ratio of 3.33. The firm’s 50-day moving average is $70.61 and its 200-day moving average is $56.44. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -26.18 and a beta of 0.99. Establishment Labs Holdings Inc. has a 52-week low of $26.56 and a 52-week high of $78.24.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. BTIG Research lifted their price objective on shares of Establishment Labs from $81.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Citigroup lifted their price target on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Mizuho boosted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Canaccord Genuity Group raised their price objective on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. lifted their target price on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $78.86.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.